Vita Mark II

09/01/1995 - "Of the first 29 eyes of the 29 enrolled patients implanted with their initial Mark II device, 28 (97%) had no progression of retinitis at the 4-week postoperative examination. "
09/01/1995 - "This small, uncontrolled pilot study indicates that the Mark II (1 mg/hour) sustained-release intravitreal ganciclovir device is effective for local control of CMV retinitis."
09/01/1995 - "Over a 15-month time period, a total of 39 Mark II intravitreal ganciclovir devices were placed in 35 eyes of 29 patients with a diagnosis of CMV retinitis. "

07/01/2015 - "The IPS Empress CAD and IPS e.max CAD showed higher fracture resistance compared with CEREC VITABLOCS Mark II. The cyclic fatigue loading negatively influenced only IPS e.max CAD. "
07/01/2015 - "According to a t test, there was no statistical difference in the fracture resistance with and without cyclic fatigue loading for CEREC VITABLOCS Mark II and IPS Empress CAD (P > .05). "
07/01/2015 - "According to a Tukey test (α = .05), the fracture resistance findings with or without cyclic fatigue loading were as follows, respectively: CEREC VITABLOCKS Mark II (405 N/454 N) was statistically lower than IPS Empress CAD (1169 N/1240 N) and IPS e.max CAD (1378 N/1025 N) (P < .05). "
08/01/2006 - "Hertzian's contact technique (WC spheres r = 3.18 mm) was used to investigate the cyclic fatigue of Vita mark II machinable ceramic. "
08/01/2006 - "To investigate the cyclic fatigue modes of Vita mark II machinable ceramics under Hertzian's contact. "

02/01/1999 - "A pilot study was then conducted to estimate the minimum CID of the Health Utilities Index (HUI) Mark II, and to compare the observed between-group differences observed in a recent randomised trial of an acute stroke intervention with this benchmark. "

04/01/1995 - "The purpose of this study was to assess the accuracy of the ENDEX in comparison with a traditional device, the RCM Mark II. The lengths of 61 canals with various contents (vital pulp, necrotic pulp, pus/exudate, sodium hypochlorite, and water) were determined in vivo. "

07/01/1999 - "To compare preference assessments that were made by using the EuroQol EQ-5D and the Health Utilities Index Mark II. 561 patients in a randomized trial of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. "